F-1: Psyence Biomedical Files for Resale of Over 50 Million Common Shares

Psyence Biomedical registers for the potential resale of over 50 million common shares by selling securityholders, including shares issuable to White Lion Capital under an equity line of credit.

Summary

• Psyence Biomedical has filed a registration statement for the potential offer and sale of 50,575,028 common shares by selling securityholders.
• This includes up to 50,375,000 shares issuable to White Lion Capital under a Common Shares Purchase Agreement, which establishes an equity line of credit of up to $25 million.
• The registration also covers 3,000 shares issued to Donohoe Advisory Associates LLC, 25,000 shares issued to Outside The Box Capital Inc., and an additional 172,028 shares issued to Outside The Box Capital Inc. for past services.
• The company will not receive any proceeds from the sale of shares by the selling securityholders, except potentially from sales to White Lion under the purchase agreement.
• The actual number of shares issuable to White Lion will vary depending on the market price of the Common Shares sold to White Lion under the White Lion Purchase Agreement and are subject to the further limitations set forth in the White Lion Purchase Agreement.
• The company's common shares trade on the Nasdaq Global Market under the symbol PBM.
• The company is a foreign private issuer and an emerging growth company, subject to reduced public company reporting requirements.

Sentiment

Score: 5

Explanation: The document is neutral in tone, primarily focused on outlining the details of the share resale and the agreement with White Lion Capital. The potential dilution risk is a concern, but the access to capital is a positive.

Positives

• The equity line of credit with White Lion Capital provides potential access to up to $25 million in funding.
• The company is a foreign private issuer and an emerging growth company, subject to reduced public company reporting requirements.

Negatives

• The offering represents a significant number of outstanding shares, which could depress the market price.
• The company will not receive proceeds from the resale of shares by selling securityholders, except potentially from sales to White Lion.
• The actual proceeds from White Lion may be less than this amount, depending on the number of Common Shares sold and the price at which the Common Shares are sold.

Risks

• The securities being offered represent vastly more than the number of our outstanding Common Shares, and the sales of such securities, or the perception that those sales might occur, could depress the market price of our Common Shares and could impair our ability to raise capital through the sale of additional equity securities.
• The securities being offered in this prospectus represent a substantial percentage of our outstanding Common Shares, and the sales of such shares, or the perception that these sales could occur, could cause the market price of our Common Shares to decline significantly.
• It is not possible to predict the actual number of shares we will sell under the White Lion Purchase Agreement to White Lion, or the actual gross proceeds resulting from those sales.
• Investors who buy shares in this offering at different times will likely pay different prices.
• The issuance of shares to White Lion and sales of a substantial number of our securities in the public market by White Lion and/or by our existing shareholders could cause the price of our Common Shares to fall.
• We have broad discretion in the use of the net proceeds we receive from the sale of shares to White Lion and may not use them effectively.
• Certain of our shareholders purchased their respective Common Shares at prices lower than the current market price for our Common Shares and may therefore experience a positive rate of return on their investment, even if our public shareholders, who invested approximately $10.00 per Common Share, would experience a negative rate of return on their investment.
• If we fail to meet applicable continued listing requirements, Nasdaq may delist our Common Shares from trading, in which case the liquidity and market price of our Common Shares could decline.
• The market price and trading volume of the Common Shares may be volatile and could decline significantly.
• Public Warrants are exercisable for Common Shares, which would increase the number of shares eligible for future resale in the public market and result in dilution to its shareholders.
• The requirements of being a public company may strain the Companys resources, divert the Company managements attention and affect the Companys ability to attract and retain qualified board members.
• The Company qualifies as a foreign private issuer within the meaning of the rules under the Exchange Act, and as such the Company is exempt from certain provisions applicable to United States domestic public companies.
• Psyence currently reports financial results under IFRS, which differs in certain significant respects from U.S. GAAP.
• You may face difficulties in protecting your interests, and your ability to protect your rights through U.S. courts may be limited, because the Company is incorporated under the laws of Canada, the Company conducts substantially all of its operations and a majority of its directors and executive officers reside outside of the United States.
• It is not expected that the Company will pay dividends in the foreseeable future.

Future Outlook

The company may receive gross proceeds of up to $25.0 million from the sale of our Common Shares to White Lion pursuant to the White Lion Purchase Agreement after the date of this prospectus.

Industry Context

The announcement reflects the ongoing capital-raising activities common among clinical-stage biotechnology companies, particularly those in the emerging psychedelic therapeutics sector.

Comparison to Industry Standards

• The equity line of credit with White Lion is a financing mechanism used by companies to access capital as needed, similar to arrangements seen with other small-cap biotech firms.
• Comparable companies in the psychedelic space, such as Atai Life Sciences and Mind Medicine (MindMed), have also utilized various financing strategies, including public offerings and private placements, to fund their clinical trials and operations.
• The potential dilution from the resale of shares is a common concern for investors in such companies, as it can impact the stock price.

Stakeholder Impact

• Shareholders may experience dilution due to the potential issuance of a large number of shares.
• The company's ability to raise capital in the future could be affected by the potential downward pressure on the stock price.
• The company's operations may benefit from the potential access to additional funding.

Next Steps

• The selling securityholders may sell or otherwise dispose of the Common Shares described in this prospectus in a number of different ways and at varying prices.
• The company intends to actively monitor its MVLS and MVPHS and will evaluate available options to regain compliance with the Nasdaq continued listing standards.
• The Company intends to consider its available options to resolve the Companys noncompliance with the Minimum Bid Price Rule.

Keywords

Common Shares, White Lion Capital, Resale, Equity Line, Prospectus, Psyence Biomedical